Jordan M. Winter

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Figure 4 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 9 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 1 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 4 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 2 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Figure 5 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Figure 3 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 6 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 11 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 8 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 12 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Figure 6 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 7 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 5 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 10 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Supplemental Figure 3 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Figure 1 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Figure 2 from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Data from Increased Glucose Availability Sensitizes Pancreatic Cancer to Macrophage-Targeting Immunotherapies

  2026-06-23

• Figure S2 from IDH1 Inhibition Potentiates Chemotherapy Efficacy in Pancreatic Cancer

  2026-06-17